[Mammaprint]
Cuadros-Celorrio M, Llanos-Mendez A, Villegas-Portero R
Record ID 32011000518
Spanish
Authors' recommendations:
The published evidence supports MammaPrintR results as being a better predictor of risk of metastasis at 5-10 years than tumour characteristics or clinically based prognostic systems. Nevertheless, there is no evidence that allows conclusions to be drawn on the clinical utility of the MammaPrintR analysis in those patients for whom thebenefit of chemotherapy is augured a priori.
Also, the clinical applicability of the results obtained with MammaPrintR in groups of patients treated in a homogenous way is unknown, it being a difficult decision to reject chemotherapy in those cases for which the array predicts a low risk of metastasis.
These questions could be resolved with the MINDACT clinical trial, started in 2006 and which will finalize in 2016.
Details
Project Status:
Completed
URL for project:
https://www.aetsa.org/publicacion/mammaprint/
Year Published:
2010
URL for published report:
https://www.aetsa.org/download/publicaciones/antiguas/AETSA_2007-02-17_Mammaprint.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Neoplasm Metastasis
- Neoplasm Staging
- Predictive Value of Tests
Contact
Organisation Name:
Andalusian Health Technology Assessment Area
Contact Address:
Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name:
aetsa.csalud@juntadeandalucia.es
Contact Email:
aetsa.csalud@juntadeandalucia.es
Copyright:
Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.